{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:16:55Z","timestamp":1787224615986,"version":"build-2736575974"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jconrel.2024.02.025","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T11:26:04Z","timestamp":1708514764000},"page":"52-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment"],"prefix":"10.1016","volume":"368","author":[{"given":"Weiran","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiancheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huining","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2024.02.025_bb0005","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1200\/JCO.2012.44.4711","article-title":"Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial","volume":"31","author":"Allegra","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0010","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.1021\/acsnano.0c01676","article-title":"Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis","volume":"14","author":"Guo","year":"2020","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0015","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1007\/s00384-021-03888-9","article-title":"The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study","volume":"36","author":"Akdeniz","year":"2021","journal-title":"Int. J. Color. Dis."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00561","article-title":"PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome","volume":"8","author":"Alsaab","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0030","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1021\/acsnano.2c12600","article-title":"Chemoimmunological cascade cancer therapy using fluorine assembly nanomedicine","volume":"17","author":"Zhang","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0035","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1200\/JCO.21.02500","article-title":"Esophagogastric cancers: integrating immunotherapy therapy into current practice","volume":"40","author":"Patel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0040","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1080\/10717544.2020.1837294","article-title":"Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid-polymer hybrid nanoparticles","volume":"27","author":"Fu","year":"2020","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0045","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijpharm.2019.06.030","article-title":"Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy","volume":"566","author":"Wan","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0050","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2021.06.005","article-title":"A cyclodextrin-based nanoformulation achieves co-delivery of ginsenoside Rg3 and quercetin for chemo-immunotherapy in colorectal cancer","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0055","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41467-020-14425-7","article-title":"Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors","volume":"11","author":"Huang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0060","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3109\/07357907.2015.1104689","article-title":"XELOX vs. FOLFOX in metastatic colorectal cancer: an updated meta-analysis","volume":"34","author":"Guo","year":"2016","journal-title":"Cancer Investig."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0065","first-page":"1032","article-title":"Comparison the incidence and severity of side effects profile of FOLFOX and DCF regimens in gastric cancer patients, Iran","volume":"18","author":"Salehifar","year":"2019","journal-title":"J. Pharm. Res."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0070","article-title":"Recent progress of novel nanotechnology challenging the multidrug resistance of cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"Suppl. 10","key":"10.1016\/j.jconrel.2024.02.025_bb0075","doi-asserted-by":"crossref","first-page":"x315","DOI":"10.1093\/annonc\/mdl280","article-title":"Chemoresistance in solid tumours","volume":"17","author":"Wilson","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02022","article-title":"PD-L1 distribution and perspective for cancer immunotherapy-blockade, knockdown, or inhibition","volume":"10","author":"Wu","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0085","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol. Mol. Biol. R"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0090","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1517\/17425247.2014.926886","article-title":"RNA interference technology for anti-VEGF treatment","volume":"11","author":"Chen","year":"2014","journal-title":"Expert Opin. Drug Del."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0095","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11427-018-9438-y","article-title":"siRNA therapeutics: a clinical reality","volume":"63","author":"Saw","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0100","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-021-01032-w","article-title":"Intrapleural nano-immunotherapy promotes innate and adaptive immune responses to enhance anti-PD-L1 therapy for malignant pleural effusion","volume":"17","author":"Liu","year":"2022","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0105","article-title":"Nanotechnology-enhanced immunotherapy for metastatic cancer","volume":"2","author":"Zhang","year":"2021","journal-title":"Innovation (N Y)"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0110","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202004172","article-title":"Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy","volume":"16","author":"Wang","year":"2020","journal-title":"Small"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.colsurfb.2019.04.035","article-title":"Dual drug loaded liposome bearing apigenin and 5-fluorouracil for synergistic therapeutic efficacy in colorectal cancer","volume":"180","author":"Sen","year":"2019","journal-title":"Colloid Surf. B"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0120","doi-asserted-by":"crossref","first-page":"918","DOI":"10.7150\/thno.14689","article-title":"Current and future theranostic applications of the lipid-calcium-phosphate nanoparticle platform","volume":"6","author":"Satterlee","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/0008-5472.CAN-21-2269","article-title":"Nanoparticle delivery of miR-122 inhibits colorectal cancer liver metastasis","volume":"82","author":"Sendi","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0130","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2020.05.005","article-title":"Membrane-core nanoparticles for cancer nanomedicine","volume":"156","author":"Guo","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0135","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1038\/s41467-021-23466-5","article-title":"Systemic metastasis-targeted nanotherapeutic reinforces tumor surgical resection and chemotherapy","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.120690","article-title":"Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy","volume":"270","author":"Ling","year":"2021","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0145","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.xphs.2015.10.026","article-title":"Preparation, characterization, and antitumor activities of miriplatin-loaded liposomes","volume":"105","author":"Liu","year":"2016","journal-title":"J. Pharm. Sci-Us"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0150","first-page":"287","article-title":"Mechanisms of action of FdUMP[10]: metabolite activation and thymidylate synthase inhibition","volume":"18","author":"Bijnsdorp","year":"2007","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0155","article-title":"Multifunctional nano-biomaterials for cancer therapy via inducing enhanced immunogenic cell death, small","author":"Chen","year":"2023","journal-title":"Methods"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0160","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1021\/acsnano.1c09794","article-title":"Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma","volume":"16","author":"Liu","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0165","article-title":"GE11 peptide as an active targeting agent in antitumor therapy: a minireview","volume":"10","author":"Genta","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0170","doi-asserted-by":"crossref","first-page":"8459","DOI":"10.1016\/j.biomaterials.2013.07.050","article-title":"Combinational delivery of c-myc siRNA and nucleoside analogs in a single, synthetic nanocarrier for targeted cancer therapy","volume":"34","author":"Zhang","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0175","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1021\/acsabm.9b01147","article-title":"Enhanced wound healing via collagen-turnover-driven transfer of PDGF-BB gene in a murine wound model","volume":"3","author":"Thapa","year":"2020","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0180","doi-asserted-by":"crossref","first-page":"13033","DOI":"10.1039\/C6NR04034A","article-title":"Systemic delivery of siRNA by hyaluronan-functionalized calcium phosphate nanoparticles for tumor-targeted therapy","volume":"8","author":"Qiu","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0185","article-title":"Immunogenic cell death inducing metal complexes for cancer therapy","author":"Zhang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0190","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cac2.12066","article-title":"A new mouse esophageal cancer cell line (mEC25)-derived pre-clinical syngeneic tumor model for immunotherapy","volume":"40","author":"Huang","year":"2020","journal-title":"Cancer Commun. (Lond. England)"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0195","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/bjc.2013.604","article-title":"The potential contribution of tumour-related factors to the development of FOLFOX-induced sinusoidal obstruction syndrome","volume":"109","author":"Robinson","year":"2013","journal-title":"Brit. J. Cancer"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0200","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/jns.12432","article-title":"Platinum accumulation in oxaliplatin-induced peripheral neuropathy","volume":"26","author":"Wei","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0205","first-page":"1","article-title":"Oxaliplatin-induced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature","volume":"2015","author":"Moskovitz","year":"2015","journal-title":"Case Rep. Oncol. Med."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0210","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.3390\/molecules13081551","article-title":"5-fluorouracil: mechanisms of resistance and reversal strategies","volume":"13","author":"Zhang","year":"2008","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0215","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.1989.7.7.890","article-title":"Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer","volume":"7","author":"Swain","year":"1989","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0225","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-020-01297-0","article-title":"Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma","volume":"20","author":"Guo","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jconrel.2024.02.025_bb0230","doi-asserted-by":"crossref","DOI":"10.1021\/acs.nanolett.2c02161","article-title":"Natural polyphenols-platinum nanocomplexes stimulate immune system for combination cancer therapy","author":"Xiang","year":"2022","journal-title":"Nano Lett."},{"key":"10.1016\/j.jconrel.2024.02.025_bb0235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365924001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T21:34:30Z","timestamp":1738100070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365924001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":47,"alternative-id":["S0168365924001123"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.025","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2024.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}